FEXINIDAZOLE
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
US9758488 is an issued fexinidazole synthesis PROCESS, not unrestricted substance protection. PCT 2012-11-22 plus 32 PTA days gives 2032-12-24; 8th-year maintenance payment dated 2025-01-13. Preserve this API sourcing/process tail after full-scope ODE; canine leishmaniosis use is excluded.
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| US9758488 | 2032-12-24 | CLAIM_REVIEW_NOT_EXACT_OB_LISTING — | N | N | PROCESS US9758488 is an issued fexinidazole synthesis PROCESS, not unrestricted substance protection. PCT 2012-11-22 plus 32 PTA days gives 2032-12-24; 8th-year maintenance payment dated 2025-01-13. Preserve this API sourcing/process tail after full-scope ODE; canine leishmaniosis use is excluded. | — | — | — |
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| NCE | — | 2026-07-16 | Active-moiety submission/approval barrier across uses. | Y | Y | — | — | Source |
| NCE | 2021-07-16 | 2026-07-16 | Active-moiety submission/approval barrier across uses. | Y | Y | 2026-07-16 | — | Source |
| ODE-359 | — | 2028-07-16 | FOR THE TREATMENT OF BOTH THE FIRST-STAGE (HEMOLYMPHATIC) AND SECOND-STAGE (MENINGOENCEPHALITIC) HUMAN AFRICAN TRYPANOSOMIASIS (HAT) DUE TO TRYPANOSOMA BRUCEI GAMBIENSE IN PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 20 KG | Y | Y | — | — | Source |
| ODE-359 | 2021-07-16 | 2028-07-16 | FOR THE TREATMENT OF BOTH THE FIRST-STAGE (HEMOLYMPHATIC) AND SECOND-STAGE (MENINGOENCEPHALITIC) HUMAN AFRICAN TRYPANOSOMIASIS (HAT) DUE TO TRYPANOSOMA BRUCEI GAMBIENSE IN PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 20 KG | Y | Y | 2028-07-16 | — | Source |
2026-10-13 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: ANNUALS_AND_MONTHLY_REVIEWED
2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| No generic approval facts are linked to this product. | |||||||
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 0 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No final-approval records are linked to this product. | ||||||
Decision evidence (4)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| PATENT | 2032-12-24 | FTO_TAIL | US9758488 is an issued fexinidazole synthesis PROCESS, not unrestricted substance protection. PCT 2012-11-22 plus 32 PTA days gives 2032-12-24; 8th-year maintenance payment dated 2025-01-13. Preserve this API sourcing/process tail after full-scope ODE; canine leishmaniosis use is excluded. | Source |
| REGULATORY_EXCLUSIVITY | 2026-07-16 | SCOPE_CONTEXT | Active-moiety submission/approval barrier across uses. | Source |
| REGULATORY_EXCLUSIVITY | 2028-07-16 | CANONICAL_ANCHOR | FOR THE TREATMENT OF BOTH THE FIRST-STAGE (HEMOLYMPHATIC) AND SECOND-STAGE (MENINGOENCEPHALITIC) HUMAN AFRICAN TRYPANOSOMIASIS (HAT) DUE TO TRYPANOSOMA BRUCEI GAMBIENSE IN PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 20 KG | Source |
| REGULATORY_STATUS | 2028-07-16 | CANONICAL_DECISION | US9758488 is an issued fexinidazole synthesis PROCESS, not unrestricted substance protection. PCT 2012-11-22 plus 32 PTA days gives 2032-12-24; 8th-year maintenance payment dated 2025-01-13. Preserve this API sourcing/process tail after full-scope ODE; canine leishmaniosis use is excluded. | Source |
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
No litigation or settlement record currently linked to this product.